CASPIAN RELEASES NEW EVIDENCE OF VERICHIP LIES AND DECEPTION
FOR IMMEDIATE RELEASE
June 3, 2008
Group's Latest Report Sets Record Straight on Chip Implants, Cancer, and more
Opponents of the VeriChip implant are launching a new offensive against the controversial human microchip this week, amid reports that VeriChip plans to put its chipping division on the auction block. A new report titled "Microchip Implants: Answers to Frequently Asked Questions" released today by CASPIAN Consumer Privacy reveals dirty laundry the company would probably rather keep hidden as it seeks a buyer for its beleaguered product.
The 42-page report was authored by CASPIAN director Dr. Katherine Albrecht, a Harvard-educated privacy expert and long-time critic of the VeriChip. The highlight of the report is an eleven-page section titled "Cancer Cover-up" that describes a systematic pattern of lies and deception engaged by VeriChip executives in an effort to downplay the fact that implantable microchips cause cancer in laboratory animals.
The report reveals how news outlets like Time Magazine, Business Week, and the RFID Journal were used as unwitting pawns in a VeriChip scheme to spread misinformation about the cancer studies. Since research linking the product to cancer first surfaced last year, each of these publications has repeated misstatements from VeriChip company executives, in many cases printing the inaccurate statements verbatim and unchallenged.
"These were not subjective issues, they were plainly verifiable issues of fact," Albrecht said. "We were saddened to see the misstatements fall through the fact-checking cracks of these respected publications. Now that VeriChip is back in the headlines, we felt it was time to set the record straight."
VeriChip's media efforts have done little to salvage the company's public image or its financial performance, both of which plummeted after research linking the implantable microchip to cancer was widely revealed by the Associated Press in September 2007. The same company that once predicted revenues in the "billions" earned just $3,000 from its microchip implant operations in the first quarter of 2008, as patients shun the device that many are now calling the "cancer chip."
Investors have also distanced themselves from the failing company, with VeriChip's stock plummeting from a high of $10.62 last year to just over $2.00 today.
VeriChip's VP of business development, Jay McKeage, acknowledged the implant division suffers from "a substantial cash burn" and is "not sustainable on its own." As a result, he says, VeriChip plans to "shop the VeriMed / Health Link [human implantable chip] business around widely" in hopes that another company will take the unpopular product off its hands.
However, with recent blog headlines like "VeriChip Death Watch" making the rounds, Albrecht has a hard time imagining who, if anyone, will want to buy the business.
"This is a company that has engaged in a consistent pattern of making false and misleading statements," she said. "It has lied to the public, to the media, to its shareholders, and to regulatory agencies," she said, citing additional evidence from the report indicating that VeriChip hid cancer evidence from the FDA when the agency reviewed the implant's safety in 2004.
"We laid out all the evidence in our report," she added. "We want to make sure no one else gets burned by VeriChip."
ABOUT THE REPORT
CASPIAN's new report, "Microchip Implants: Answers to Frequently Asked Questions," is a comprehensive reference guide to implantable microchips in animals and humans. It provides thoroughly-researched, footnoted answers to 85 of the most commonly asked questions about the implantable microchip, including religious, privacy, social, and health questions. The report concludes with a list of recommendations for patients, pet owners, and policy makers affected by the device.
The new report is available for free download on the group's AntiChips.com website at: http://www.antichips.com/faq/index.html
While on the website, readers are encouraged to download Dr. Albrecht's comprehensive 52-page overview of the studies, "Microchip-Induced Tumors in Laboratory Rodents and Dogs: A Review of the Literature 1990-2006," and to review scanned copies of the original documents.
ABOUT CASPIAN
CASPIAN (Consumers Against Supermarket Privacy Invasion and Numbering) is a grass-roots consumer group fighting retail surveillance schemes since 1999 and irresponsible RFID use since 2002. With thousands of members in all 50 U.S. states and over 30 countries worldwide, CASPIAN seeks to educate consumers about marketing strategies that invade their privacy and encourage privacy-conscious shopping habits across the retail spectrum.
http://www.spychips.com/
http://www.antichips.com/
http://www.nocards.org/
You're welcome to duplicate and distribute this message to others who may find it of interest.
http://omega.twoday.net/search?q=Verichip
http://omega.twoday.net/search?q=microchip
http://omega.twoday.net/search?q=implant
http://omega.twoday.net/search?q=RFID
http://omega.twoday.net/search?q=Katherine+Albrecht
June 3, 2008
Group's Latest Report Sets Record Straight on Chip Implants, Cancer, and more
Opponents of the VeriChip implant are launching a new offensive against the controversial human microchip this week, amid reports that VeriChip plans to put its chipping division on the auction block. A new report titled "Microchip Implants: Answers to Frequently Asked Questions" released today by CASPIAN Consumer Privacy reveals dirty laundry the company would probably rather keep hidden as it seeks a buyer for its beleaguered product.
The 42-page report was authored by CASPIAN director Dr. Katherine Albrecht, a Harvard-educated privacy expert and long-time critic of the VeriChip. The highlight of the report is an eleven-page section titled "Cancer Cover-up" that describes a systematic pattern of lies and deception engaged by VeriChip executives in an effort to downplay the fact that implantable microchips cause cancer in laboratory animals.
The report reveals how news outlets like Time Magazine, Business Week, and the RFID Journal were used as unwitting pawns in a VeriChip scheme to spread misinformation about the cancer studies. Since research linking the product to cancer first surfaced last year, each of these publications has repeated misstatements from VeriChip company executives, in many cases printing the inaccurate statements verbatim and unchallenged.
"These were not subjective issues, they were plainly verifiable issues of fact," Albrecht said. "We were saddened to see the misstatements fall through the fact-checking cracks of these respected publications. Now that VeriChip is back in the headlines, we felt it was time to set the record straight."
VeriChip's media efforts have done little to salvage the company's public image or its financial performance, both of which plummeted after research linking the implantable microchip to cancer was widely revealed by the Associated Press in September 2007. The same company that once predicted revenues in the "billions" earned just $3,000 from its microchip implant operations in the first quarter of 2008, as patients shun the device that many are now calling the "cancer chip."
Investors have also distanced themselves from the failing company, with VeriChip's stock plummeting from a high of $10.62 last year to just over $2.00 today.
VeriChip's VP of business development, Jay McKeage, acknowledged the implant division suffers from "a substantial cash burn" and is "not sustainable on its own." As a result, he says, VeriChip plans to "shop the VeriMed / Health Link [human implantable chip] business around widely" in hopes that another company will take the unpopular product off its hands.
However, with recent blog headlines like "VeriChip Death Watch" making the rounds, Albrecht has a hard time imagining who, if anyone, will want to buy the business.
"This is a company that has engaged in a consistent pattern of making false and misleading statements," she said. "It has lied to the public, to the media, to its shareholders, and to regulatory agencies," she said, citing additional evidence from the report indicating that VeriChip hid cancer evidence from the FDA when the agency reviewed the implant's safety in 2004.
"We laid out all the evidence in our report," she added. "We want to make sure no one else gets burned by VeriChip."
ABOUT THE REPORT
CASPIAN's new report, "Microchip Implants: Answers to Frequently Asked Questions," is a comprehensive reference guide to implantable microchips in animals and humans. It provides thoroughly-researched, footnoted answers to 85 of the most commonly asked questions about the implantable microchip, including religious, privacy, social, and health questions. The report concludes with a list of recommendations for patients, pet owners, and policy makers affected by the device.
The new report is available for free download on the group's AntiChips.com website at: http://www.antichips.com/faq/index.html
While on the website, readers are encouraged to download Dr. Albrecht's comprehensive 52-page overview of the studies, "Microchip-Induced Tumors in Laboratory Rodents and Dogs: A Review of the Literature 1990-2006," and to review scanned copies of the original documents.
ABOUT CASPIAN
CASPIAN (Consumers Against Supermarket Privacy Invasion and Numbering) is a grass-roots consumer group fighting retail surveillance schemes since 1999 and irresponsible RFID use since 2002. With thousands of members in all 50 U.S. states and over 30 countries worldwide, CASPIAN seeks to educate consumers about marketing strategies that invade their privacy and encourage privacy-conscious shopping habits across the retail spectrum.
http://www.spychips.com/
http://www.antichips.com/
http://www.nocards.org/
You're welcome to duplicate and distribute this message to others who may find it of interest.
http://omega.twoday.net/search?q=Verichip
http://omega.twoday.net/search?q=microchip
http://omega.twoday.net/search?q=implant
http://omega.twoday.net/search?q=RFID
http://omega.twoday.net/search?q=Katherine+Albrecht
Starmail - 3. Jun, 22:53
